BRIEF-Polyrizon Structures Clinical Strategy For Its Allergy Blocker Ahead Of FDA Pre-Submission Meeting

Reuters
27 Mar
BRIEF-Polyrizon Structures Clinical <a href="https://laohu8.com/S/MSTR">Strategy</a> For Its Allergy Blocker Ahead Of FDA Pre-Submission Meeting

March 27 (Reuters) - Polyrizon Ltd PLRZ.O:

  • POLYRIZON STRUCTURES CLINICAL STRATEGY FOR ITS ALLERGY BLOCKER AHEAD OF FDA PRE-SUBMISSION MEETING

  • POLYRIZON LTD - EXPECTS TO INITIATE CLINICAL TRIALS IN U.S. AND EUROPE IN LATE 2025

Source text: ID:nGNXb6nl5X

Further company coverage: PLRZ.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10